###begin article-title 0
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 135 140 <span type="species:ncbi:4932">yeast</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes
###end article-title 0
###begin title 1
Introduction:
###end title 1
###begin p 2
###xml 432 440 420 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
###xml 294 299 <span type="species:ncbi:4932">yeast</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 359 364 <span type="species:ncbi:9606">human</span>
Recombinant alpha(1)-proteinase inhibitor, clinically developed for inhalative augmentation therapy in patients with alpha(1)-proteinase inhibitor deficiency or cystic fibrosis, may directly contribute to leukocyte accumulation as it may function as a chemoattractant. The migratory effects of yeast-derived human recombinant alpha(1)-proteinase inhibitor on human peripheral blood neutrophils and eosinophils were therefore tested in vitro.
###end p 2
###begin title 3
Materials and Methods:
###end title 3
###begin p 4
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 130 135 <span type="species:ncbi:4932">yeast</span>
Human peripheral blood leukocytes were prepared from forearm venous blood and tested for migration toward various preparations of yeast-derived recombinant alpha(1)-proteinase inhibitor in modified Boyden-chamber micropore filter assays.
###end p 4
###begin title 5
Results:
###end title 5
###begin p 6
###xml 86 94 82 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 21 26 <span type="species:ncbi:4932">yeast</span>
###xml 47 52 <span type="species:ncbi:9606">human</span>
No direct effects of yeast-derived recombinant human alpha(1)-proteinase inhibitor on in vitro migration of isolated neutrophils or eosinophils were seen.
###end p 6
###begin title 7
Conclusions:
###end title 7
###begin p 8
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
The lack of direct chemotactic effects of recombinant human alpha(1)-proteinase inhibitor despite anti-inflammatory effects in other biological activities of leukocytes may contribute to the preserved antibacterial defense mechanisms observed in patients under experimental augmentation therapy with inhaled alpha(1)-proteinase inhibitor.
###end p 8
###begin title 9
Keywords:
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 187 188 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 337 339 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 389 390 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 425 427 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 770 771 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 191 197 <span type="species:ncbi:9606">People</span>
In the healthy human lung, alpha(1)-proteinase inhibitor (A1PI) is present at high concentrations and acts as an anti-protease screen to prevent the deleterious effects of free elastase [2]. People with a deficiency of A1PI are at risk for emphysema as a result of low levels of A1PI in the lungs in the presence of neutrophil elastase [25]. In cystic fibrosis airways, A1PI is complexed [3] and proteolytically inactivated [26], resulting in an imbalance of proteases and anti-proteases. The discovery of the structure and function of the A1PI protein and its subsequent isolation and purification have allowed replacement therapy (so-called "augmentation therapy") aimed at preventing the progression of the lung disease associated with deficiency or cystic fibrosis [9]. Isolation of the gene and advances in gene therapy further broadened the potential for specific therapy by the synthesis of recombinant A1PI.
###end p 11
###begin p 12
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 470 478 470 478 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 1.</label>
###xml 539 540 535 536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 478 540 478 536 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="13">Human plasmatic &#945;-1-antitrypsin preparation modifications<sup>1</sup></p>
###xml 478 540 478 536 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="13">Human plasmatic &#945;-1-antitrypsin preparation modifications<sup>1</sup></p></caption>
###xml 540 540 536 536 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 540 550 536 544 <th xmlns:xlink="http://www.w3.org/1999/xlink">Aralast&#174;</th>
###xml 550 562 544 554 <th xmlns:xlink="http://www.w3.org/1999/xlink">Prolastin&#174;</th>
###xml 562 572 554 562 <th xmlns:xlink="http://www.w3.org/1999/xlink">Zemaira&#174;</th>
###xml 540 572 536 562 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th/><th>Aralast&#174;</th><th>Prolastin&#174;</th><th>Zemaira&#174;</th></tr>
###xml 540 572 536 562 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th/><th>Aralast&#174;</th><th>Prolastin&#174;</th><th>Zemaira&#174;</th></tr></thead>
###xml 572 579 562 569 <td xmlns:xlink="http://www.w3.org/1999/xlink">Company</td>
###xml 579 596 569 586 <td xmlns:xlink="http://www.w3.org/1999/xlink">Baxter Healthcare</td>
###xml 596 620 586 610 <td xmlns:xlink="http://www.w3.org/1999/xlink">Talecris Biotherapeutics</td>
###xml 620 631 610 621 <td xmlns:xlink="http://www.w3.org/1999/xlink">CSL Behring</td>
###xml 572 631 562 621 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Company</td><td>Baxter Healthcare</td><td>Talecris Biotherapeutics</td><td>CSL Behring</td></tr>
###xml 631 655 621 645 <td xmlns:xlink="http://www.w3.org/1999/xlink">Plasma half-lives (days)</td>
###xml 655 664 645 652 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.9&#177;1.2</td>
###xml 664 673 652 659 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.1&#177;0.5</td>
###xml 673 682 659 666 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.1&#177;2.4</td>
###xml 631 682 621 666 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Plasma half-lives (days)</td><td>5.9&#177;1.2</td><td>5.1&#177;0.5</td><td>5.1&#177;2.4</td></tr>
###xml 682 732 666 716 <td xmlns:xlink="http://www.w3.org/1999/xlink">Specific activity (mg functional A1PI/mg protein)*</td>
###xml 732 739 716 721 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8805;0.55</td>
###xml 739 746 721 726 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8805;0.35</td>
###xml 746 753 726 731 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8805;0.07</td>
###xml 682 753 666 731 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Specific activity (mg functional A1PI/mg protein)*</td><td>&#8805;0.55</td><td>&#8805;0.35</td><td>&#8805;0.07</td></tr>
###xml 753 766 731 744 <td xmlns:xlink="http://www.w3.org/1999/xlink">Glycoisoforms</td>
###xml 766 785 744 763 <td xmlns:xlink="http://www.w3.org/1999/xlink">No major difference</td>
###xml 785 785 763 763 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 785 785 763 763 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 753 785 731 763 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Glycoisoforms</td><td>No major difference</td><td/><td/></tr>
###xml 785 810 763 788 <td xmlns:xlink="http://www.w3.org/1999/xlink">Deamidation (qualitative)</td>
###xml 810 820 788 798 <td xmlns:xlink="http://www.w3.org/1999/xlink">Detectable</td>
###xml 820 820 798 798 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 820 820 798 798 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 785 820 763 798 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Deamidation (qualitative)</td><td>Detectable</td><td/><td/></tr>
###xml 820 849 798 827 <td xmlns:xlink="http://www.w3.org/1999/xlink">Deamidation (quantitative, %)</td>
###xml 849 850 827 828 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 850 852 828 830 <td xmlns:xlink="http://www.w3.org/1999/xlink">10</td>
###xml 852 853 830 831 <td xmlns:xlink="http://www.w3.org/1999/xlink">7</td>
###xml 820 853 798 831 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Deamidation (quantitative, %)</td><td>6</td><td>10</td><td>7</td></tr>
###xml 853 882 831 860 <td xmlns:xlink="http://www.w3.org/1999/xlink">C-terminal Lys truncation (%)</td>
###xml 882 884 860 862 <td xmlns:xlink="http://www.w3.org/1999/xlink">67</td>
###xml 884 885 862 863 <td xmlns:xlink="http://www.w3.org/1999/xlink">2</td>
###xml 885 886 863 864 <td xmlns:xlink="http://www.w3.org/1999/xlink">6</td>
###xml 853 886 831 864 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>C-terminal Lys truncation (%)</td><td>67</td><td>2</td><td>6</td></tr>
###xml 886 907 864 885 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cys232 cysteinylation</td>
###xml 907 908 885 886 <td xmlns:xlink="http://www.w3.org/1999/xlink">+</td>
###xml 908 909 886 887 <td xmlns:xlink="http://www.w3.org/1999/xlink">+</td>
###xml 909 910 887 888 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</td>
###xml 886 910 864 888 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Cys232 cysteinylation</td><td>+</td><td>+</td><td>&#8722;</td></tr>
###xml 910 929 888 907 <td xmlns:xlink="http://www.w3.org/1999/xlink">Methionin oxidation</td>
###xml 929 972 907 950 <td xmlns:xlink="http://www.w3.org/1999/xlink">Not observed (A1PI fully functional active)</td>
###xml 972 972 950 950 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 972 972 950 950 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 910 972 888 950 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Methionin oxidation</td><td>Not observed (A1PI fully functional active)</td><td/><td/></tr>
###xml 572 972 562 950 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Company</td><td>Baxter Healthcare</td><td>Talecris Biotherapeutics</td><td>CSL Behring</td></tr><tr><td>Plasma half-lives (days)</td><td>5.9&#177;1.2</td><td>5.1&#177;0.5</td><td>5.1&#177;2.4</td></tr><tr><td>Specific activity (mg functional A1PI/mg protein)*</td><td>&#8805;0.55</td><td>&#8805;0.35</td><td>&#8805;0.07</td></tr><tr><td>Glycoisoforms</td><td>No major difference</td><td/><td/></tr><tr><td>Deamidation (qualitative)</td><td>Detectable</td><td/><td/></tr><tr><td>Deamidation (quantitative, %)</td><td>6</td><td>10</td><td>7</td></tr><tr><td>C-terminal Lys truncation (%)</td><td>67</td><td>2</td><td>6</td></tr><tr><td>Cys232 cysteinylation</td><td>+</td><td>+</td><td>&#8722;</td></tr><tr><td>Methionin oxidation</td><td>Not observed (A1PI fully functional active)</td><td/><td/></tr></tbody>
###xml 540 972 536 950 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th/><th>Aralast&#174;</th><th>Prolastin&#174;</th><th>Zemaira&#174;</th></tr></thead><tbody><tr><td>Company</td><td>Baxter Healthcare</td><td>Talecris Biotherapeutics</td><td>CSL Behring</td></tr><tr><td>Plasma half-lives (days)</td><td>5.9&#177;1.2</td><td>5.1&#177;0.5</td><td>5.1&#177;2.4</td></tr><tr><td>Specific activity (mg functional A1PI/mg protein)*</td><td>&#8805;0.55</td><td>&#8805;0.35</td><td>&#8805;0.07</td></tr><tr><td>Glycoisoforms</td><td>No major difference</td><td/><td/></tr><tr><td>Deamidation (qualitative)</td><td>Detectable</td><td/><td/></tr><tr><td>Deamidation (quantitative, %)</td><td>6</td><td>10</td><td>7</td></tr><tr><td>C-terminal Lys truncation (%)</td><td>67</td><td>2</td><td>6</td></tr><tr><td>Cys232 cysteinylation</td><td>+</td><td>+</td><td>&#8722;</td></tr><tr><td>Methionin oxidation</td><td>Not observed (A1PI fully functional active)</td><td/><td/></tr></tbody></table>
###xml 972 973 950 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 1046 1048 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 972 1050 950 1028 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="14"><sup>1</sup> Data in part taken from product specifications or from Kolarich et al. [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
###xml 1050 1070 1028 1048 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="15">* Plasma A1PI, 0.02.</p>
###xml 972 1070 950 1048 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="14"><sup>1</sup> Data in part taken from product specifications or from Kolarich et al. [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p textid="15">* Plasma A1PI, 0.02.</p></table-wrap-foot>
###xml 470 1070 470 1048 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1.</label><caption><p textid="13">Human plasmatic &#945;-1-antitrypsin preparation modifications<sup>1</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Aralast&#174;</th><th>Prolastin&#174;</th><th>Zemaira&#174;</th></tr></thead><tbody><tr><td>Company</td><td>Baxter Healthcare</td><td>Talecris Biotherapeutics</td><td>CSL Behring</td></tr><tr><td>Plasma half-lives (days)</td><td>5.9&#177;1.2</td><td>5.1&#177;0.5</td><td>5.1&#177;2.4</td></tr><tr><td>Specific activity (mg functional A1PI/mg protein)*</td><td>&#8805;0.55</td><td>&#8805;0.35</td><td>&#8805;0.07</td></tr><tr><td>Glycoisoforms</td><td>No major difference</td><td/><td/></tr><tr><td>Deamidation (qualitative)</td><td>Detectable</td><td/><td/></tr><tr><td>Deamidation (quantitative, %)</td><td>6</td><td>10</td><td>7</td></tr><tr><td>C-terminal Lys truncation (%)</td><td>67</td><td>2</td><td>6</td></tr><tr><td>Cys232 cysteinylation</td><td>+</td><td>+</td><td>&#8722;</td></tr><tr><td>Methionin oxidation</td><td>Not observed (A1PI fully functional active)</td><td/><td/></tr></tbody></table><table-wrap-foot><p textid="14"><sup>1</sup> Data in part taken from product specifications or from Kolarich et al. [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p textid="15">* Plasma A1PI, 0.02.</p></table-wrap-foot></table-wrap>
###xml 403 409 <span type="species:ncbi:9606">humans</span>
###xml 478 483 <span type="species:ncbi:9606">Human</span>
Therapeutic concentrates are prepared from the blood plasma of blood donors and are the only form of A1PI available for therapy so far. All commercially available A1PI products differ from the A1PI directly analyzed in plasma (summarized in Table 1). The observed differences between the products most likely do not play a substantial biologic role because all three products have similar half-lives in humans and neutralize neutrophil elastase to the same extent [12]. Table 1.Human plasmatic alpha-1-antitrypsin preparation modifications1Aralast(R)Prolastin(R)Zemaira(R)CompanyBaxter HealthcareTalecris BiotherapeuticsCSL BehringPlasma half-lives (days)5.9+/-1.25.1+/-0.55.1+/-2.4Specific activity (mg functional A1PI/mg protein)*>/=0.55>/=0.35>/=0.07GlycoisoformsNo major differenceDeamidation (qualitative)DetectableDeamidation (quantitative, %)6107C-terminal Lys truncation (%)6726Cys232 cysteinylation++-Methionin oxidationNot observed (A1PI fully functional active)1 Data in part taken from product specifications or from Kolarich et al. [12].* Plasma A1PI, 0.02.
###end p 12
###begin p 13
###xml 61 62 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human plasmatic alpha-1-antitrypsin preparation modifications1
###end p 13
###begin p 14
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
1 Data in part taken from product specifications or from Kolarich et al. [12].
###end p 14
###begin p 15
* Plasma A1PI, 0.02.
###end p 15
###begin p 16
###xml 447 469 447 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa</italic>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 258 263 <span type="species:ncbi:9606">human</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
###xml 447 469 <span type="species:ncbi:287">Pseudomonas aeruginosa</span>
To attenuate the deleterious effects of free elastase on pulmonary structure and host defense mechanisms more effectively, the inhalation of A1PI has been proposed as a therapeutic strategy in both A1PI deficiency and cystic fibrosis patients. Inhalation of human plasmatic A1PI increased A1PI levels in adult patients with cystic fibrosis and decreased the levels of elastase activity, neutrophils, pro-inflammatory cytokines, and the numbers of Pseudomonas aeruginosa [7]. Trends of reduced elastase levels and inflammation had already been observed in another study using recombinant A1PI [16].
###end p 16
###begin p 17
###xml 65 66 65 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 677 678 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 197 202 <span type="species:ncbi:9606">human</span>
###xml 663 668 <span type="species:ncbi:9606">human</span>
Recombinant technology has also been used to produce human A1PI [4, 11, 14, 17], as regulatory authorities have recommended the development of recombinant counterparts to blood-derived therapeutic human proteins [18]. Recombinant A1PI is not yet commercially available, but it is under investigation as a therapy for A1PI deficiency for both intravenous application and inhalation. In the development of drug therapy for A1PI deficiency, aerosol administration of recombinant proteins to the airways has been the preferred method of delivery because of their shorter half-lives after intravenous infusion compared with that of A1PI purified and concentrated from human plasma [5].
###end p 17
###begin p 18
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 368 376 361 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 467 474 460 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 476 478 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 709 711 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 838 846 831 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 897 905 890 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 762 767 <span type="species:ncbi:9606">human</span>
###xml 792 797 <span type="species:ncbi:9606">human</span>
###xml 875 880 <span type="species:ncbi:4932">yeast</span>
Recent studies suggest a role for A1PI as an anti-inflammatory modulator [19] independent of its antiproteinase effect, which may explain some of the observations in recent clinical studies. A1PI inhibited lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha and interleukin (IL)-1beta release from monocytes dose dependently and IL-8 release from neutrophils in vitro. Furthermore, A1PI instillation after LPS challenge prevented LPS-induced IL-8 production in vivo [19]. It is currently unknown to what extend recombinant A1PI affects leukocyte chemotaxis. Alteration of leukocyte migration could have relevance to the cells' pulmonary accumulation, which is of major pathophysiological importance [10]. We therefore investigated the direct effects of human recombinant (rh)A1PI on human peripheral blood granulocyte chemotaxis in vitro. We report that rhA1PI from yeast does not induce in vitro chemotaxis of leukocytes in micropore filter assays.
###end p 18
###begin title 19
Materials and Methods
###end title 19
###begin title 20
rhA1PI preparation and other material
###end title 20
###begin p 21
###xml 188 191 188 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">213</sup>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 85 90 <span type="species:ncbi:4932">yeast</span>
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 193 198 <span type="species:ncbi:9606">human</span>
###xml 291 296 <span type="species:ncbi:9606">human</span>
###xml 350 355 <span type="species:ncbi:9606">human</span>
The rhA1PI used in this study, supplied by Baxter (Vienna, Austria), was produced by yeast transformed with an expressing plasmid containing a human cDNA encoding the mature normal Ml (Val213) human A1PI protein [21]. This rhA1PI preparation has a molecular mass of about 45 kDa, similar to human plasma A1PI, and functions in an identical manner as human plasma rhA1PI as an inhibitor of neutrophil elastase [1].
###end p 21
###begin p 22
###xml 231 237 <span type="species:ncbi:9913">Bovine</span>
###xml 448 452 <span type="species:ncbi:9913">calf</span>
Formyl-Met-Leu-Phe, dextran, and penicillin-streptomycin were from Sigma Chemical Corp. (St. Louis, MO, USA). RANTES was from Pepro Tech EC Ltd. (London, UK). RPMI 1640 with phenol red purchased from Biochrom AG (Berlin, Germany). Bovine serum albumin (BSA) was from Dade Behring (Marburg, Germany). Lymphoprep(R) was from Nycomed Pharma AS (Oslo, Norway). MACS separation columns and microbeads were from Miltenyi Biotech (Auburn, CA, USA). Fetal calf serum and phosphate-buffered saline (PBS) were from PAA Laboratories GmbH (Pasching, Austria). Trypsin-EDTA in HBSS from Gibco (Paisley, UK). The microchemotaxis chambers were from Neuroprobe (Bethesda, MD, USA) and the cellulose nitrate filters were from Sartorius (Goettingen, Germany).
###end p 22
###begin title 23
Preparation of granulocytes
###end title 23
###begin p 24
###xml 264 265 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 551 552 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 658 663 <span type="species:ncbi:9606">human</span>
Neutrophils and eosinophils were obtained from peripheral EDTA-anticoagulated blood of healthy volunteers by Lymphoprep(R) density gradient centrifugation followed by dextran sedimentation and hypotonic lysis of contaminating erythrocytes as described previously [6]. The neutrophil preparations yielded above 95% neutrophils (by morphology in GIEMSA stains) of more than 99% viability (by trypan dye exclusion). For the eosinophil preparation, the cells were resuspended in 50 ml of ice-cold MACS buffer (PBS with 5 mmol/l EDTA and 0.5% BSA) per 5x107 cells and an equal volume of MACS colloidal superparamagnetic microbeads conjugated with monoclonal anti-human CD16 monoclonal antibody was added and incubated (30 min, 4degreesC). Recommended volumes of ice-cold MACS buffer were added to the cell-microbead mixture and the cell suspension was loaded onto the separation column. The eluate containing CD16-negative eosinophils was collected, washed, resuspended in RPMI 1640/0.5% BSA, and the separation procedure was repeated to increase purity. The purity of the sorted eosinophils was 98% as determined by morphology and FACS analysis. Contaminating cells were 1% lymphocytes, 1% neutrophils and basophils, and negligible numbers of monocytes/macrophages.
###end p 24
###begin title 25
Migration assay
###end title 25
###begin p 26
###xml 219 220 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 294 295 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 808 809 797 798 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The migration assays were performed using a modified 48-well Boyden microchemotaxis chamber (Neuroprobe, Bethesda, MD, USA) in which a 5-microm-pore-size cellulose nitrate filter separated the upper and lower chambers [6]. Neutrophils or eosinophils were resuspended in RPMI 1640/0.5% BSA (1x106 cells/ml). Fifty mul of the cell suspension were placed into the upper chamber and allowed to migrate toward 10 nmol/l of formyl-Met-Leu-Phe or toward 10 ng/l of RANTES chemokines, which were used as positive-control chemoattractants at optimal concentrations for neutrophils and eosinophils, respectively; various dilutions of rhA1PI probes 1-4; or respiratory cell culture supernatants placed in the lower chamber for 30 min (neutrophils) or 60 min (eosinophils) at 37degreesC in a humidified atmosphere (5% CO2). After the migration period, the nitrocellulose filters were dehydrated, fixed, and stained with hematoxylin. The migration depth of the cells into the filters was quantified by means of microscopy, measuring the distance (micromm) from the surface of the filter to the leading front of three cells. Data are expressed as the chemotaxis index, which is the ratio of the distances of directed and random migration of neutrophils or eosinophils into the nitrocellulose filters.
###end p 26
###begin title 27
Statistical methods
###end title 27
###begin p 28
Data are expressed as mean +/- standard error of the mean (SEM). Means were compared by the Mann-Whitney U-test and Kruskal-Wallis ANOVA. A difference with p<0.05 was considered to be significant. Statistical analyses were performed using the StatView software package (Abacus Concepts, Berkeley, CA, USA).
###end p 28
###begin title 29
Results and Discussion
###end title 29
###begin p 30
###xml 95 103 95 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 503 504 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 158 163 <span type="species:ncbi:9606">human</span>
###xml 327 332 <span type="species:ncbi:4932">yeast</span>
To investigate whether granulocyte recruitment to the lung could be a direct effect of rhA1PI, in vitro neutrophil or eosinophil chemotaxis was assessed. The human plasmatic A1PI protein in a range of concentrations from 0.1-3 mg/ml had no effect on granulocyte chemotaxis (data not shown). Data from different preparations of yeast rhA1PI and a vehicle (MOCK) preparation which contained the preparation's solution but devoid of the protein are shown for neutrophils (Fig. 1) and for eosinophils (Fig. 2). The positive-control attractants 10 nmol/l of formyl-Met-Leu-Phe and 10 ng/l of RANTES for neutrophils and eosinophils, respectively, significantly stimulated directed migration. Neither of the rhA1PI preparations affected migration in a significant manner at doses ranging from attomolar to micromolar concentrations. The MOCK preparation had no effect on eosinophil migration. It stimulated neutrophil directed migration to some extent, reaching statistical significance at the highest dose tested, corresponding to the rhA1PI vehicle concentration of >1 micromol/l.
###end p 30
###begin p 31
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human peripheral blood neutrophil migration toward the chemoattractant formyl-Met-Leu-Phe or alpha(1)-antitrypsin (rAAT). Mean distances of random migration were 66, 77, 74, and 85 microm for rAAT-1, rAAT-2, rAAT-3, and MOC, respectively. *p<0.05, Mann-Whitney U-test versus medium after multiple group comparison by using the Kruskal-Wallis test.
###end p 31
###begin p 32
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human peripheral blood eosinophil migration toward the chemoattractant RANTES or alpha(1)-antitrypsin (rAAT). Mean distances of random migration were 62, 68, 69, and 72 microm for rAAT-1, rAAT-2, rAAT-3, and MOC, respectively. *p<0.05, Mann-Whitney U-test versus medium after multiple group comparison by using the Kruskal-Wallis test.
###end p 32
###begin p 33
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 1164 1166 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1553 1560 1553 1560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 1781 1782 1781 1782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1784 1786 1784 1786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 515 520 <span type="species:ncbi:9606">human</span>
###xml 1246 1251 <span type="species:ncbi:4932">yeast</span>
###xml 1374 1379 <span type="species:ncbi:4932">yeast</span>
###xml 1469 1474 <span type="species:ncbi:9606">human</span>
###xml 1886 1891 <span type="species:ncbi:4932">yeast</span>
Inhaled rhA1PI may directly contribute to leukocyte accumulation in the lung as human plasmatic A1PI may function as a neutrophil chemoattractant when polymerized [15, 20, 22]. However, no direct effect was seen for rhA1PI on neutrophil or eosinophil chemotaxis. Polymerization of rhA1PI has not been reported so far; consequently, induction of migration by rhA1PI if polymerized remains speculative. The present results indicate, however, that at high concentrations, a crude preparation of vehicle (MOCK) induced human neutrophil, but not eosinophil migration to some extent, suggesting the potential of eventual contaminants to modify migration. Since eosinophils did not respond to the vehicle, the contaminating compound(s) may be specific and involve molecular mechanisms. As the rhA1PI was unable to induce the same effect, it may be that the dose equivalence between the two types of samples was not given. Another possibility is that the immunomodulatory activity of rhA1PI on leukocytes heterogeneously cross-deactivates chemotactic contamination of the vehicle, such as that described between non-chemotactic tumor necrosis factor-alpha and chemokines [24]. Despite the application of good manufacturing practice, contamination of the yeast-derived rhA1PI formulation may thus potentially induce inflammatory responses after aerosol inhalation. Host responses to yeast are mediated by Toll-like receptor 2 (TLR2), which is normally expressed by a variety of human cells. Cell-surface TLR2 activation is known to induce neutrophil activation. In vivo indirect chemotactic effects may be exerted by induced mediators that are released from respiratory cells, including IL-8, which is a potent granulocyte attractant responsible for leukocyte accumulation in lung airways [8, 13]. Thus for the evaluation of safety, direct and indirect mechanisms by which aerosol inhalation of yeast-derived rhA1PI formulations may adversely affect lung inflammation have to be taken into account.
###end p 33
###begin p 34
###xml 399 423 399 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae</italic>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 299 304 <span type="species:ncbi:4932">Yeast</span>
###xml 370 375 <span type="species:ncbi:4932">Yeast</span>
###xml 399 423 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 445 450 <span type="species:ncbi:4932">yeast</span>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
###xml 667 672 <span type="species:ncbi:9606">human</span>
Given the concerns related to the limited supply of pooled human plasma and the potential for the transmission of infectious agents, some manufacturers are particularly investigating alternative sources of augmentation therapy. Transgenic or recombinant sources could be used in inhalation devices. Yeast expression systems are well suited for the production of rhA1PI. Yeast rhA1PI manufactured in Saccharomyces cerevisiae (baker's or brewer's yeast) [4] was tested in a clinical trial when administered by aerosol inhalation to patients with rhA1PI deficiency associated with hereditary emphysema. According to the sponsors' information, results from this phase 1A human study evaluating safety and immunogenicity showed that rhA1PI was well tolerated and a phase 1B/2A clinical trial has been said to be underway to evaluate its effects [1].
###end p 34
###begin p 35
###xml 34 42 34 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 12 17 <span type="species:ncbi:4932">yeast</span>
###xml 141 146 <span type="species:ncbi:4932">yeast</span>
rhA1PI from yeast does not induce in vitro chemotaxis of granulocytes in micropore filter assays. Contents in the preparation's vehicle from yeast may still have the potential to induce migration of leukocytes because TLR-2 on other airway cells may indirectly contribute to leukocyte accumulation by release of leukocyte attractants such as IL-8. In consequence, the proinflammatory potential of rhA1PI aerosol therapy will have to be assessed clinically in order to assure its safety. There remains the need for high standards for purification of recombinant proteins.
###end p 35
###begin p 36
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 198 203 <span type="species:ncbi:9940">sheep</span>
###xml 243 248 <span type="species:ncbi:9940">sheep</span>
###xml 357 362 <span type="species:ncbi:9606">human</span>
###xml 420 425 <span type="species:ncbi:9940">sheep</span>
###xml 619 624 <span type="species:ncbi:9606">human</span>
###xml 738 743 <span type="species:ncbi:9606">human</span>
Strategies to evaluate immune-mediated toxic effects of preparations of transgenic protein should be established to ensure the development of safe and effective therapies. To evaluate the safety of sheep-derived transgenic rhA1PI, aerosolized sheep-derived transgenic rhA1PI was administered in two clinical studies [23]. Systemic antibody responses to non-human protein that was present in very low concentrations in a sheep-derived transgenic rhA1PI formulation were observed after aerosol inhalation. The clinical symptoms and secondary antibody responses suggest that re-exposure could result in intolerance of non-human-protein impurities [23]. These observations may represent an important obstacle to the development of transgenic human proteins for therapeutic use.
###end p 36
###begin p 37
###xml 337 345 <span type="species:ncbi:9606">patients</span>
In conclusion, the present study explored if rhA1PI directly activates lung inflammatory granulocyte migration. The result of no direct chemotactic effects of A1PI despite its recently described anti-inflammatory affects in other biological activities of leukocytes may explain the preserved antibacterial defense mechanisms observed in patients under experimental inhalative augmentation therapy with rhA1PI.
###end p 37
###begin title 38
Acknowledgment
###end title 38
###begin p 39
The study was supported in part by the "Verein zur Forderung von Forschung und Fortbildung in klinischer Kardiologie und Intensivmedizin - Innsbruck, Austria".
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
Proteases and antiproteases in cystic fibrosis: pathogenetic considerations and therapeutic strategies
###end article-title 41
###begin article-title 42
###xml 48 56 <span type="species:ncbi:9606">children</span>
Protease-antiprotease imbalance in the lungs of children with cystic fibrosis
###end article-title 42
###begin article-title 43
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 52 57 <span type="species:ncbi:4932">yeast</span>
###xml 58 82 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Expression of human alpha 1-antitrypsin cDNA in the yeast Saccharomyces cerevisiae
###end article-title 43
###begin article-title 44
Potential role of inhibitors of neutrophil elastase in treating diseases of the airway
###end article-title 44
###begin article-title 45
###xml 55 60 <span type="species:ncbi:9606">human</span>
Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C
###end article-title 45
###begin article-title 46
###xml 77 85 <span type="species:ncbi:9606">patients</span>
alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients
###end article-title 46
###begin article-title 47
Corticosteroid and cytokines synergistically enhance Toll-like receptor 2 expression in respiratory epithelial cells
###end article-title 47
###begin article-title 48
Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency
###end article-title 48
###begin article-title 49
Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages
###end article-title 49
###begin article-title 50
Production of serpins using baculovirus expression systems
###end article-title 50
###begin article-title 51
Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy
###end article-title 51
###begin article-title 52
Role of Toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils
###end article-title 52
###begin article-title 53
###xml 92 97 <span type="species:ncbi:9606">human</span>
Application of vortex flow adsorption technology to intein-mediated recovery of recombinant human alpha1-antitrypsin
###end article-title 53
###begin article-title 54
Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo
###end article-title 54
###begin article-title 55
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis
###end article-title 55
###begin article-title 56
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 56 60 <span type="species:ncbi:4530">rice</span>
Production of human alpha-1-antitrypsin from transgenic rice cell culture in a membrane bioreactor
###end article-title 56
###begin article-title 57
###xml 52 57 <span type="species:ncbi:9606">human</span>
Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release
###end article-title 57
###begin article-title 58
###xml 53 58 <span type="species:ncbi:9606">human</span>
Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema
###end article-title 58
###begin article-title 59
###xml 28 33 <span type="species:ncbi:4932">yeast</span>
Production of serpins using yeast expression systems
###end article-title 59
###begin article-title 60
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 52 57 <span type="species:ncbi:9606">human</span>
Do native and polymeric alpha1-antitrypsin activate human neutrophils in vitro?
###end article-title 60
###begin article-title 61
###xml 44 49 <span type="species:ncbi:9606">human</span>
Antibody response to aerosolized transgenic human alpha1-antitrypsin
###end article-title 61
###begin article-title 62
###xml 52 57 <span type="species:ncbi:9606">human</span>
Receptor blockade as a mechanism of deactivation of human neutrophils by pepstatin and formyl-Met-Leu-Phe
###end article-title 62
###begin article-title 63
Alpha1-antitrypsin deficiency
###end article-title 63
###begin article-title 64
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Proteolytic inactivation of alpha 1-proteinase inhibitor in infected bronchial secretions from patients with cystic fibrosis
###end article-title 64

